NCT01169584 - Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

November 30, 2014

Conditions

NeuroblastomaRhabdomyosarcomaLymphomaWilm's TumorEwing's Sarcoma

Interventions

DRUG

Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.

Trial Locations (2)

Cincinnati Children's Hospital Medical Center, Cincinnati

Texas Children's Hospital, Houston